Monitoring and improving hepatitis C health outcomes among people with hepatitis C

在澳大利亚，丙型肝炎与相当大的发病率和死亡率有关，卫生保健系统花费92亿美元。在明年，容易产生副作用的丙型肝炎疗法将被简单，可耐受，无干扰素的疗法（治愈90%）所取代，可以逆转肝病进展。我的目标是进一步发展我在与HCV流行病学和治疗策略相关的人群健康方面的既定研究计划，特别关注PWID。

In Australia, hepatitis C is associated with considerable morbidity and mortality, costing $9.2 billion to the health care system. In the next year, side-effect prone hepatitis C therapies will be replaced with simple, tolerable, interferon-free therapies (cure >90%) that can reverse liver disease progression. My goal is to further develop my established research program in population-health related to HCV epidemiology, and therapeutic strategies, with a specific focus on PWID.